BriaCell Therapeutics Corp is a clinical-stage biotechnology company developing targeted immunotherapies to transform cancer care. Its Bria-IMT targeted immunotherapy is being developed in combination with the immune checkpoint inhibitor Retifanlimab in a pivotal Phase 3 study in metastatic breast cancer. The Company's operations focus on the research and development of its immunotherapy product candidates and related supporting activities.
Last trade$3.50
Day change+$0.20 (+6.06%)
Day range$3.27 – $3.68
Volume104,648
Market cap$29M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$28.82M
Price / earnings
—
Price / book
1.76×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.53×
Profitability
Earnings per share
-$4.00
Return on assets
-148.03%
Return on equity
-212.82%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.76×
Quick ratio
2.76×
Cash ratio
1.23×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$28.78M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BCTX, quarterly periods
Line item
Q4 FY2026 Jul 31, 2026
Q3 FY2026 Apr 30, 2026
Q2 FY2026 Jan 31, 2026
Q1 FY2026 Oct 31, 2025
Q4 FY2025 Jul 31, 2025
Q3 FY2025 Apr 30, 2025
Q2 FY2025 Jan 31, 2025
Q1 FY2025 Oct 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.05M
$1.65M
$1.48M
$1.64M
$1.44M
$1.52M
$1.48M
$1.49M
Research and development
$10.53M
$5.97M
$6.05M
$6.68M
$7.11M
$4.81M
$5.68M
$3.67M
Total operating expenses
$12.58M
$7.62M
$7.53M
$8.32M
$8.55M
$6.33M
$7.17M
$5.15M
Operating income
-$12.58M
-$7.62M
-$7.53M
-$8.32M
-$8.55M
-$6.33M
-$7.17M
-$5.15M
Interest expense
-$29.63K
$0
$0
$0
-$36.98K
$0
$0
$0
Income before taxes
-$12.51M
-$7.24M
-$7.3M
-$8.28M
-$8.16M
-$6.22M
-$6.34M
-$5.83M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$12.51M
-$7.24M
-$7.3M
-$8.28M
-$8.16M
-$6.22M
-$6.34M
-$5.83M
Net income attributable to common shareholders
-$12.32M
-$7.16M
-$7.22M
-$8.2M
-$8.09M
-$6.13M
-$6.29M
-$5.8M
EBITDA
-$12.55M
-$7.59M
-$7.5M
-$8.3M
-$8.53M
-$6.3M
-$7.14M
-$5.13M
Basic earnings per share
-$1.52
-$0.99
-$2.58
-$4.35
-$9.28
-$16.42
-$23.31
-$32.67
Diluted earnings per share
-$1.52
-$0.99
-$2.58
-$4.35
-$9.28
-$16.42
-$23.31
-$32.67
Recent news
Company coverage with links to the original publishers.
BriaCell Therapeutics and its subsidiary BriaPro presented preclinical findings at SITC 2026 demonstrating positive results for their immunotherapy programs. Bria-OTS+ showed broad immune activation and sustained cancer-cell killing across multiple tumor models, while BP-80 demonstrated good tolerability in primate studies. TILsRx constructs showed enhanced binding affinity for PD-L1, supporting continued development of their immunotherapy pipeline for breast and prostate cancer indications.
BriaCell Therapeutics Corp. announced a best-efforts offering of 1,449,300 common shares at $3.25 per share, expected to raise approximately $4.7 million in gross proceeds. The offering is scheduled to close on June 2, 2026, with net proceeds designated for working capital, general corporate purposes, and advancement of business objectives. ThinkEquity is serving as the sole placement agent.
BriaCell reported promising Phase 2 survival data for Bria-IMT immunotherapy in metastatic breast cancer, showing improved median overall survival compared to Trodelvy and single-agent chemotherapy across triple-negative and hormone receptor-positive breast cancer subtypes.
The article discusses the rise in cancer incidence and the need for better treatments, as well as the potential impact of budget reductions and new tariffs on innovation. Several oncology companies, including Oncolytics Biotech, Sutro Biopharma, BriaCell Therapeutics, and Tempus AI, have reported notable updates in 2025.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.